UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Annals of oncology, 2011-07, Vol.22 (7), p.1622-1627

2011

Link zum Volltext

Verfügbarkeit prüfen

Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients

Leukemia, 2007-02, Vol.21 (2), p.340-350

2007

Link zum Volltext

Verfügbarkeit prüfen

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi

Annals of oncology, 2013-08, Vol.24 (8), p.2108-2112

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Annals of oncology, 2013-11, Vol.24 (11), p.2892-2897

2013

Link zum Volltext

Verfügbarkeit prüfen

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2018-10, Vol.29 (Supplement_4), p.iv30-iv40

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)

Annals of oncology, 2011-03, Vol.22 (3), p.689-695

2011

Link zum Volltext

Verfügbarkeit prüfen

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients

Annals of oncology, 2006-08, Vol.17 (8), p.1296-1300

2006

Link zum Volltext

Verfügbarkeit prüfen

Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group

Annals of oncology, 2009-12, Vol.20 (12), p.1993-1999

2009

Link zum Volltext

Verfügbarkeit prüfen

SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias

Annals of oncology, 2014-12, Vol.25 (12), p.2339-2350

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

Annals of oncology, 2017-09, Vol.28 (9), p.2169-2178

2017

Link zum Volltext

Verfügbarkeit prüfen

Hodgkin's lymphoma: the pathologist's viewpoint

Journal of clinical pathology, 2002-03, Vol.55 (3), p.162-176

2002

Link zum Volltext

Verfügbarkeit prüfen

A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (URBAN): IMPACT OF COVID‐19 PANDEMIC ON ENROLLMENT AND SAFETY

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays

Leukemia, 2012-03, Vol.26 (3), p.499-508

2012

Link zum Volltext

Verfügbarkeit prüfen

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Annals of oncology, 2022-03, Vol.33 (3), p.288-298

2022

Link zum Volltext

Verfügbarkeit prüfen

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi149-vi154

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Annals of oncology, 2018-05, Vol.29 (5), p.1266-1272

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

The New England journal of medicine, 2015-10, Vol.373 (18), p.1733-1747

2015

Link zum Volltext

Verfügbarkeit prüfen

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

British journal of cancer, 2004-08, Vol.91 (5), p.850-854

2004

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients

Annals of oncology, 2008-04, Vol.19 (4), p.769-773

2008

Link zum Volltext

Verfügbarkeit prüfen

Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2015-09, Vol.26, p.v100-v107

2015

Link zum Volltext

Verfügbarkeit prüfen

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients

Annals of oncology, 2010-06, Vol.21 (6), p.1173-1178

2010

Link zum Volltext

Verfügbarkeit prüfen

Survival in HIV‐infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study

HIV medicine, 2018-09, Vol.19 (8), p.523-531

2018

Link zum Volltext

Verfügbarkeit prüfen

Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies

Journal of clinical pathology, 2008-11, Vol.61 (11), p.1160-1167

2008

Link zum Volltext

Verfügbarkeit prüfen

The importance of assessing blood tumour burden in cutaneous T‐cell lymphoma

British journal of dermatology (1951), 2021-07, Vol.185 (1), p.19-25

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 498

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(485)
Mit Volltextzugriff
(371)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(293)
Life Sciences & Biomedicine
(272)
Science & Technology
(272)
Male
(196)
Female
(194)
Middle Aged
(183)
Hematology
(178)
Adult
(167)
Biological And Medical Sciences
(137)
Medical Sciences
(137)
Oncology
(137)
Aged
(124)
Hematologic And Hematopoietic Diseases
(88)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(85)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(82)
Treatment Outcome
(80)
Lymphoma
(77)
Chemotherapy
(61)
Pharmacology. Drug Treatments
(59)
Adolescent
(58)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients

Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group

SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

Hodgkin's lymphoma: the pathologist's viewpoint

A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (URBAN): IMPACT OF COVID‐19 PANDEMIC ON ENROLLMENT AND SAFETY

Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients

Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients

Survival in HIV‐infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study

Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies

The importance of assessing blood tumour burden in cutaneous T‐cell lymphoma

Suchergebnisse filtern